Triumph Capital Management’s VanEck Biotech ETF BBH Stock Holding History

Triumph Capital Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.63K	Hold	8	–	–	﹤0.01%	1594
2026 Q1	$1.5K	Hold	8	–	–	﹤0.01%	1575
2025 Q4	$1.51K	Buy	+8	New	+$1.48K	﹤0.01%	1515

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Triumph Capital Management's BBH Position: Q2 2026 in Review

Triumph Capital Management held its VanEck Biotech ETF (BBH) position steady in Q2 2026 at 8 shares worth $1.63K. The position accounts for ﹤0.01% of the portfolio, ranked #1594.

Triumph Capital Management first reported a position in BBH in Q4 2025 and has held it in 3 quarters since. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

Triumph Capital Management held 8 shares of VanEck Biotech ETF worth $1.63K as of Q2 2026.
Triumph Capital Management left its VanEck Biotech ETF share count unchanged in Q2 2026.
VanEck Biotech ETF made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1594 holding.
Triumph Capital Management first reported a position in VanEck Biotech ETF in Q4 2025 and has held it in 3 quarters since.
110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.